Vertex Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 67 to 71 Friday — a welcome improvement, but still shy of the 80 or better score you look for.
IBD's unique rating identifies price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the top-performing stocks tend to have an 80 or better RS Rating as they launch their largest price moves. See if Vertex Pharmaceuticals can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Vertex Pharmaceuticals is building a flat base with a 510.63 entry. See if it can break out in volume at least 40% higher than normal.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 2% to 7%. Revenue rose from 6% to 12%.
The company holds the No. 15 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
